Technical Analysis for DMAC - DiaMedica Therapeutics Inc.

Grade Last Price % Change Price Change
B 3.47 -5.19% -0.19
DMAC closed down 5.19 percent on Wednesday, May 8, 2024, on 2.3 times normal volume. Note that the stock is in overbought territory based on its Slow Stochastic indicator (14, 3, 3) -- so don't be surprised if it goes sideways or a pulls back.
Earnings due: May 9
*** please verify all earnings dates ***
0 Watchers
Watchlist Portfolio

Trend Table & Recent EOD Trading Signals

ADX Long Term Intermediate Term Short Term
Weak or Absent Up Up Up

Date Alert Name Type % Chg
Stochastic Sell Signal Bearish 0.00%
Slingshot Bullish Bullish Swing Setup 0.00%
Wide Range Bar Range Expansion 0.00%
Upper Bollinger Band Walk Strength 0.00%
Wide Bands Range Expansion 0.00%
Above Upper BB Strength 0.00%
Overbought Stochastic Strength 0.00%
Upper Bollinger Band Touch Strength 0.00%
Pocket Pivot Bullish Swing Setup -5.19%
Volume Surge Other -5.19%

   Recent Intraday Alerts

Alert Time
2x Volume Pace about 20 hours ago
Down 10% about 20 hours ago
Down 2 ATRs about 20 hours ago
60 Minute Opening Range Breakdown about 21 hours ago
Gapped Down (Full) about 21 hours ago

Free Daily (Stock) Chart Reading

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.

Profile

DiaMedica Therapeutics Inc., a clinical-stage biopharmaceutical company, engages in the development of treatments for neurological and kidney diseases. The company's lead product is DM199, a recombinant human tissue kallikrein-1 protein, which is in Phase II clinical trials for the treatment of acute ischemic stroke and kidney injury indications. It is also developing DM199 for the treatment vascular dementia. In addition, the company is developing DM300, which is in pre-clinical stage for the treatment for acute pancreatitis. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.
Classification

Sector: Healthcare
Industry: Biotechnology
Keywords: Biotechnology Biopharmaceutical Life Sciences Pharmacy Kidney Disease Stroke Dementia Ischemia Kallikrein Pancreatitis Acute Pancreatitis

Is DMAC a Buy, Sell or Hold?

Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength

Indicators

Indicator Value
52 Week High 4.75
52 Week Low 1.58
Average Volume 44,543
200-Day Moving Average 2.77
50-Day Moving Average 2.80
20-Day Moving Average 2.68
10-Day Moving Average 2.91
Average True Range 0.23
RSI (14) 69.23
ADX 20.13
+DI 38.39
-DI 25.86
Chandelier Exit (Long, 3 ATRs) 3.04
Chandelier Exit (Short, 3 ATRs) 2.95
Upper Bollinger Bands 3.45
Lower Bollinger Band 1.91
Percent B (%b) 1.01
BandWidth 57.48
MACD Line 0.16
MACD Signal Line 0.03
MACD Histogram 0.1351
Fundamentals Value
Market Cap 131.7 Million
Num Shares 38 Million
EPS -0.60
Price-to-Earnings (P/E) Ratio -5.78
Price-to-Sales 0.00
Price-to-Book 2.16
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 4.38
Resistance 3 (R3) 4.33 3.98 4.22
Resistance 2 (R2) 3.98 3.75 4.00 4.17
Resistance 1 (R1) 3.72 3.60 3.55 3.77 4.12
Pivot Point 3.37 3.37 3.29 3.40 3.37
Support 1 (S1) 3.12 3.14 2.95 3.17 2.82
Support 2 (S2) 2.77 3.00 2.79 2.77
Support 3 (S3) 2.52 2.77 2.72
Support 4 (S4) 2.56